GU Cancers Symp. 2014: Renal Cancer

Galectin-1 upregulates CXCR4 to promote tumor progression and poor outcome in kidney cancer - Abstract April 24, 2014

GU Cancers Symposium 2014 - Axitinib: Common questions related to real-world use of a new treatment option in advanced renal cell carcinoma - Poster February 5, 2014

GU Cancers Symposium 2014 - Heterogeneity of intermediate prognosis patients with metastatic renal cell cancer treated with sunitinib - Poster February 5, 2014

GU Cancers Symposium 2014 - Impact of angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database - Poster February 5, 2014

GU Cancers Symposium 2014 - Correlation between patient-reported fatigue and hemoglobin levels in metastatic renal cell carcinoma patients receiving sunitinib - Poster February 5, 2014

GU Cancers Symposium 2014 - Growth kinetics and outcomes of clinical T1b renal masses under active surveillance - Poster February 5, 2014

GU Cancers Symposium 2014 - Lymphopenia is an independent predictor of inferior outcome in papillary renal cell carcinoma - Poster February 5, 2014

GU Cancers Symposium 2014 - Open-label, phase II RAPTOR study of everolimus for papillary mRCC: Efficacy in type 1 and type 2 histology - Poster February 5, 2014

GU Cancers Symposium 2014 - In vitro and in vivo effects of the mTOR inhibitors everolimus and temsirolimus - Poster February 5, 2014

GU Cancers Symposium 2014 - Everolimus as second-line therapy for metastatic renal cell carcinoma after one previous VEGF-targeted therapy: Final results of the noninterventional change study - Poster February 5, 2014

GU Cancers Symposium 2014 - Biomarker analysis from a phase III trial (GOLD) of dovitinib vs sorafenibin patients with metastatic renal cell carcinoma after one prior VEGF pathway-targeted therapy and one prior mTOR inhibitor therapy - Poster February 5, 2014

GU Cancers Symposium 2014 - Second-line prescribing preferences of U.S.-based medical oncologists following first-line TKI in patients with metastatic clear cell renal cell carcinoma - Poster February 4, 2014

GU Cancers Symposium 2014 - Cell cycle progression score to predict metastatic progression of clear cell renal cell carcinoma after resection - Poster February 4, 2014

GU Cancers Symposium 2014 - Optimal targeting of the PD-1/PDL-1 pathway in metastatic kidney cancer - Session Highlights February 4, 2014

GU Cancers Symposium 2014 - Translating genomics into better cancer care - Session Highlights February 4, 2014

GU Cancers Symposium 2014 - Prognosis, prediction, and update from the International Metastatic Renal Cell Carcinoma Database Consortium - Session Highlights February 4, 2014

GU Cancers Symposium 2014 - BAP1 and PBRM1 in renal cancer - Session Highlights February 4, 2014

GU Cancers Symposium 2014 - Comprehensive molecular characteristics of clear-cell renal cell carcinoma: An update from the CGA Research Network - Session Highlights February 4, 2014

GU Cancers Symposium 2014 - A decade in review: Renal cancer - Session Highlights February 4, 2014

GU Cancers Symposium 2014 - The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in metastatic renal cell carcinoma patients previously treated with first line targeted therapy - Session Highlights February 4, 2014

Page 1 of 2